#VisualAbstract: Paclitaxel coating of endovascular devices not associated with a difference in all-cause mortality

RELATED REPORTS

1. Patients with peripheral artery disease who received a drug-coated device did not face an increased risk of death compared to those who received an uncoated device at any point during the 2+ year follow-up.

2. This finding appeared to be independent of disease severity, although the wide confidence interval was suggestive of a potential difference by subgroup.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Endovascular intervention appears to be effective in treating peripheral artery disease but is associated with a considerable risk of postprocedural restenosis. Coating balloons and stents with antiproliferative agents such as paclitaxel has been shown to reduce this risk, but the effects of drug-coated devices on patient-oriented endpoints and long-term outcomes remain unclear. The Swedish Drug Elution Trial in Peripheral Arterial Disease (SWEDEPAD) was originally designed to assess the impact of drug-coated devices on quality of life and incidence of amputation; after a recent meta-analysis revealed an increased late risk of death following application of these devices, patient recruitment was halted and an unplanned interim analysis of all-cause mortality was conducted. After a mean follow-up period of two and a half years, the percentages of patients in the drug-coated and uncoated groups who had died were found to differ by less than a single point. Deaths generally occurred at a continuous rate and did not vary between groups at any time point; further, this trend seemed to be consistent across both the chronic limb-threatening ischemia and intermittent claudication subgroups. This study had a lengthy follow-up and no patient attrition, but it was limited by an open-label design and may have been underpowered to detect differences within subgroups. Additionally, low-dose devices were used more frequently than high-dose devices, which could have attenuated any effects associated with paclitaxel. Overall, the results from this randomized trial supported the safety of paclitaxel-coated devices over the short to medium term.

Click here to read the study, published in NEJM

Relevant Reading: Risk of Death Following Application of Paclitaxel‐Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

In-Depth [randomized controlled trial]: In this multicenter, single-blind trial with recruitment from November 2014 until December 2018, 2289 adults with symptomatic peripheral artery disease caused by flow-limiting stenosis or occlusion in infrainguinal arteries were placed into one of two cohorts according to severity (chronic limb-threatening ischemia vs. intermittent claudication). These groups were then randomly assigned in a 1:1 ratio during endovascular balloon angioplasty or stenting (after guide wire placement but before dilation) to receive treatment with either a paclitaxel-coated device or an uncoated device. During a mean follow-up of 2.49 years (2.34 for chronic group and 2.77 for intermittent group), a total of 574 patients (25.1%) died. Of these, 293 belonged to the drug-coated group (1480 patients) and 281 belonged to the uncoated group (809 patients), corresponding to a hazard ratio (HR) of 1.06 (95% confidence interval [CI], 0.92 to 1.22) and a mortality rate per 100 patient-years of 10.4% and 9.8%, respectively. No between-group difference was detected in either the chronic subgroup (33.4% [249 patients] vs. 33.1% [243 patients]; HR, 1.04; 95% CI, 0.90 to 1.21) or the intermittent subgroup (10.9% [44 patients] vs. 9.4% [38 patients]; HR, 1.18; 95% CI, 0.72 to 1.93).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RelatedReports

Next Post

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

Get Full Access

Register now to get free full access to over 8000 searchable archived reports, visual abstracts, Classics Series landmark trials, weekly rewinds, and much more.

Welcome Back!

Login to your account below

Create New Account!

Fill the forms below to register

Retrieve your password

Please enter your username or email address to reset your password.